Skip to content

nightshade elimination diet on arthritis patients

The evaluation of nightshade elimination diet on inflammatory and rheumatologic markers of rheumatoid arthritis patients: single blind randomized clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230220057465N1
Enrollment
36
Registered
2023-04-08
Start date
2023-04-09
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Other specified rheumatoid arthritis

Interventions

Intervention 1: Intervention group will receive general dietary recommendations including reduce consumption of simple sugar, saturated fatty acids, red meat, refined cereals and increase consumption

Sponsors

Yasouj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: age over 18 years confirmed diagnosis of the disease by a doctor using the criteria of the American College of Rheumatology (ACR) not taking any nutritional supplements not having a diet during the study and before sampling

Exclusion criteria

Exclusion criteria: others Chronic diseases: allergy, CVD, asthma, cancer, depression, Alzheimer's psychoactive drugs consumption simultaneous disorder of RA with other rheumatoid diseases smoking changing therapeutic drugs taking nutritional supplements non-compliance with the study protocol occurrence of serious complications during the study

Design outcomes

Primary

MeasureTime frame
Complete Blood Count. Timepoint: at baseline and at the end of treatment ( week 8). Method of measurement: Cell Counter.;Hs-CRP. Timepoint: at baseline and at the end of treatment ( week 8). Method of measurement: ELISA Reader.;IL-1. Timepoint: at baseline and at the end of treatment ( week 8). Method of measurement: ELISA Reader.;ESR. Timepoint: at baseline and at the end of treatment ( week 8). Method of measurement: Westergren-Katz tube.;Clinical symptoms. Timepoint: at baseline and at the end of treatment ( week 8). Method of measurement: Using AIMS-2: Arthritis Impact Measurement Scale-2 by rheumatologist.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahboobe Hosseinikia

Yasouj University of Medical Sciences

m.hosseinikia@yahoo.com009874332251

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026